The medical device maker has completed more than 40 acquisitions in recent years, helping turn it into one of the state’s ...

Boston Scientific Corporation's acquisition of Axonics, Inc. for $3.7 billion expands urology offerings with innovative ...

Boston Scientific BSX is gaining traction in the international markets. New regulatory approvals and accretive acquisitions ...

We recently published a list of 8 Most Promising Medical Stocks According to Hedge Funds. In this article, we are going to ...

Endoscopy net sales were $678 million ... For the fourth quarter of 2024, Boston Scientific expects EPS to range between $0.64 and $0.66, compared to analyst expectations of $0.64.

The MedSurg division, which includes endoscopy, urology, and neuromodulation devices, had a 10% revenue rise to $1.48 billion. Boston Scientific Lowers FY EPS Outlook, Raises Adjusted EPS The ...

Boston Scientific (NYSE: BSX ... while Cardiovascular sales increased 25% from the same period a year ago. Endoscopy (7.8% growth), Urology (10.3%) and Neuromodulation (17%) drove MedSurg.

Neurology Sales Growth: 10% in Q3 2024. Endoscopy Sales Growth: 7% organically in Q3 2024. Boston Scientific Corp (NYSE:BSX) reported a 19% growth in operational sales and an 18% increase in ...